214 RESULTS
RESEARCH NEWS 2020-01-17 Research News Transgenic mice fail to capture many aspects of Alzheimer’s disease, and a new transcriptional study lays bare one reason. Brain cells in the two species, it turns out, respond quite differently to amyloidosis. In the January 13 Nature Medic
RESEARCH NEWS 2020-01-16 Research News Three new studies add to growing evidence that damaged blood vessels wreak havoc on the brain, but not by exacerbating Aβ deposition. One, published in JAMA Neurology on December 20, found no correlation between intracerebral atherosclerosis
RESEARCH NEWS 2020-01-16 Research News According to an article in the January 14 Cell Reports, boosting the activity of certain excitatory receptors in the brain calms epileptic activity and improves learning and memory in mouse models of disease. Jesse Hanson, Genentech Inc. in
RESEARCH NEWS 2020-01-15 Research News How do neurons die in Alzheimer’s disease? Perhaps by necroptosis, a form of programmed cell death triggered by inflammation. In the December Acta Neuropathologica, researchers led by Dietmar Thal, Bart De Strooper, and Sriram Balusu at KU L
RESEARCH NEWS 2020-01-14 Research News As if the neurodegenerative brain didn’t have enough troubles, a study published in Nature on January 8 reports that it may be swarming with highly trained cellular henchmen. Researchers led by Tony Wyss-Coray at Stanford University found cy
RESEARCH NEWS 2020-01-10 Research News A new study supports the idea that deposits of tau predict that a person’s brain will soon wither. Investigators led by Renaud La Joie and Gil Rabinovici, University of California, San Francisco, found that in people with mild Alzheimer’s di
CONFERENCE COVERAGE 2020-01-09 Conference Coverage What lies ahead for Alzheimer’s therapy development? While anti-amyloid antibodies are at last signaling some success, researchers agree that these expensive—and, thus far, at best modestly effective—biologic drugs can form only part o
CONFERENCE COVERAGE 2020-01-09 Conference Coverage This article was amended on January 10, 2020 Tau PET is prying open a window on when and where neurofibrillary tangles appear as Alzheimer’s progresses. At the 12th Clinical Trials on Alzheimer’s Disease Conference, held December 4–7 i
RESEARCH NEWS 2020-01-05 Research News In the year just past, Alzheimer’s researchers, families, and stakeholders felt renewed hope that new treatments might be within grasp. While the Lazarus story of aducanumab may or may not be enough for FDA approval this year, data from its
CONFERENCE COVERAGE 2019-12-29 Conference Coverage Though Aβ-targeted therapies hogged the limelight at this year’s Clinical Trials on Alzheimer’s Disease meeting, held December 4–7 in San Diego, California, a large handful of smaller studies had findings to report, as well. These stud
COMMUNITY NEWS 2019-12-23 Community News Continuing a steady climb in funding for Alzheimer’s research, the Senate approved a $350 million increase in funding for Alzheimer’s and dementia research at the National Institutes of Health for the 2020 fiscal year. The appropriation bil
CONFERENCE COVERAGE 2019-12-21 Conference Coverage For therapies taking aim at Alzheimer’s disease, exerting an effect in the brain seems critical. And obvious. But according to results on display at 12th Clinical Trials on Alzheimer’s Disease conference, held December 4–7 in San Diego
CONFERENCE COVERAGE 2019-12-20 Conference Coverage Anti-amyloid antibodies are at long last showing promise for treating Alzheimer’s disease, but for long-term use, researchers are seeking cheaper and easier options than monthly infusions. They want that elusive once-a-day pill. BACE i
CONFERENCE COVERAGE 2019-12-20 Conference Coverage With aducanumab’s resurrection driving renewed interest in anti-amyloid antibody therapies, researchers at the 12th Clinical Trials on Alzheimer’s Disease conference, held December 4–7 in San Diego, happily provided updates on their ow
CONFERENCE COVERAGE 2019-12-19 Conference Coverage While a suite of new CSF markers has entered a mature stage where they get validated with identical methods in large international cohorts (see previous CTAD story), much newer blood tests are catching up fast. Scientists are pushing t
